Cardiff Lexington Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CDIX research report →
Price Chart
About the company
Headquartered in Fort Lauderdale, Florida, Cardiff Lexington Corporation, which was established in 2001, offers a diverse range of services. The company provides affordable housing solutions and comprehensive tax resolution services across the United States. Its operations include the leasing and sale of mobile homes and mobile home parks, presenting an alternative to conventional housing.
- CEO
- Alex Hunt Cunningham
- IPO
- 2005
- Employees
- 17
- HQ
- Lexington, KY, US
Get TickerSpark's AI analysis on CDIX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $167.56K
- P/E
- -0.01
- PEG
- 0.00
- P/S
- 0.02
- P/B
- 0.08
- EV/EBITDA
- -7.41
- Div Yield
- 0.00%
- Gross Margin
- 58.44%
- Op Margin
- -25.24%
- Net Margin
- -137.85%
- ROE
- -305.28%
- ROIC
- -8.50%
Latest fiscal year · YoY change
- Revenue
- $11.54M+39.5%
- Gross Profit
- $7.21M+62.7%
- Op Income
- $1.10M
- Net Income
- $-6,541,895-98.1%
- EPS
- $-0.98+11.7%
- OCF Growth
- -7.5%
- FCF Growth
- -7.5%
- 52W High
- $6.00
- 52W Low
- $0.00
- 50D MA
- $0.15
- 200D MA
- $1.39
- Beta
- 1.97
- RSI (14)
- 37
- Avg Volume
- 118.22K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cardiff Lexington reported lower revenue and wider losses in Q3, while emphasizing a proposed acquisition and refinancing as the key path to solving its working-capital issues.· November 16, 2026
- Q3 revenue fell to $1.9 million from $3.1 million a year ago, pressured by fewer procedures and a lower realization rate on patient case settlements.
- Gross margin compressed to 54.2% from 62.4% last year, while operating expenses rose due in part to $370,000 of share-based compensation.
- Net loss widened to $3.2 million, driven heavily by $2.5 million of interest expense tied to higher-cost financing.
- Management’s central focus remains securing new equity and refinancing through the proposed merger with a larger healthcare platform.
- The company said the transaction would dilute existing shareholders, but management believes it could create more long-term value through a stronger balance sheet and added scale.
Third-quarter 2026 revenue was $1.9 million versus $3.1 million in Q3 2025. Gross profit was $1.0 million, or 54.2% of sales, versus $1.9 million, or 62.4%, a year ago. Total operating expenses rose to $1.6 million from $1.3 million, including $370,000 of share-based compensation versus $41,000 last year. Loss from continuing operations was $537,000 versus income of $643,000 in Q3 2025; net loss was $3.2 million versus $1.1 million, and adjusted EBITDA was a loss of $279,000 versus positive $663,000. Cash was $584,000 at September 30, 2026, and net accounts receivable were $23.4 million. Management did not give formal quarterly or full-year financial guidance; instead, it said it expects further progress on the proposed acquisition in December, with no definitive execution date yet set.
Alex Cunningham framed the quarter around long-term restructuring rather than near-term operating improvement. He said demand for services remains strong, but working-capital constraints continue to limit the company’s ability to capture that demand, so the priority is refinancing and securing sustainable working capital. He was upbeat about the proposed acquisition, calling it a “significant and critical opportunity” that could bring new equity, debt restructuring, and a more durable balance sheet, though he also stressed there are no guarantees the deal closes.
Matt Shafer focused on the income statement pressure from lower revenue and financing costs. He cited Q3 revenue of $1.9 million, gross profit of $1.0 million, operating expenses of $1.6 million, and interest expense of $2.5 million, which he said reflected higher-cost financing structures used to fund the business. On the balance sheet, he said total assets were $30.6 million, cash was $584,000, net accounts receivable were $23.4 million, and total liabilities were $29 million as of September 30, 2026.
In the only analyst question, Andrea Grieco asked whether the proposed acquisition could leave existing shareholders with a much smaller ownership stake and give new investors and sellers preferential treatment. Cunningham answered yes, acknowledging dilution and preferential rights, but argued that the trade-off may be worthwhile if the transaction creates a larger, more financially stable company with better long-term value. He said management is still weighing the deal’s financing cost, capital coming in, and the overall benefit to shareholders, while noting standalone efforts may not be enough in the long run.
Management said demand for services remains strong, and the proposed merger could bring in new equity, refinancing, and a stronger balance sheet to address persistent working-capital constraints. They also highlighted the target’s lack of appreciable debt, its complementary clinical platform, and the possibility of future ambulatory surgery center integration.
The quarter showed meaningful pressure on both revenue and profitability, with lower procedure volume, a reduced realization rate, and materially higher interest expense. Management also openly said existing shareholders will be diluted and that there is no assurance the proposed transaction will close, while working-capital constraints remain unresolved in the meantime.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 43.6%
- Shares Outstanding
- 22.05M
- Float Shares
- 9.62M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 8, 26 | Staley Louis Jack Sr. | other | 500,000 |
| Sep 8, 26 | Pennington Catherine B. | other | 500,000 |
| Sep 8, 26 | Johnson Gillard B. III | other | 500,000 |
| Apr 1, 26 | Staley Louis Jack Sr. | other | 5,000 |
| Apr 1, 26 | Pennington Catherine B. | other | 5,000 |
| Apr 1, 26 | Johnson Gillard B. III | other | 5,000 |
| Jan 29, 26 | Cunningham Alex H. | other | 556,528 |
| Jan 13, 26 | Shafer Matthew T | other | 62,500 |
| Nov 19, 25 | THOMPSON DANIEL | other | 9,192,092 |
| Nov 20, 24 | THOMPSON DANIEL | other | 510,704 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CDIX coverage
Recent articles, reports, and earnings notes.
No research on CDIX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CDIX report →Cardiff Lexington Corporation (CDIX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 16
Cardiff Lexington Corporation Announces Letter of Intent for Proposed Acquisition of Leading Musculoskeletal Healthcare Platform
accessnewswire.com · Sep 24
Cardiff Lexington Announces Second Quarter 2026 Financial Results
accessnewswire.com · Aug 12
Cardiff Lexington to Report Second Quarter 2026 Financial Results and Host Conference Call on Wednesday, August 12, 2026
accessnewswire.com · Aug 6
Cardiff Lexington Announces the Addition of Southeastern Surgery Center in Tallahassee, Florida to Nova Ortho and Spine Network
accessnewswire.com · Jun 29
Cardiff Lexington's Nova Ortho and Spine Announces New Medical Office in Stuart, Florida to Serve the Growing Treasure Coast Community
accessnewswire.com · May 20
Cardiff Lexington Announces First Quarter 2026 Financial Results
accessnewswire.com · May 19
Cardiff Lexington to Report First Quarter 2026 Financial Results and Host Conference Call on Tuesday, May 19, 2026
accessnewswire.com · May 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.